TY - JOUR
T1 - The state of immune checkpoint inhibition in urothelial carcinoma current evidence and future areas of exploration
AU - Campbell, Matthew T.
AU - Siefker-Radtke, Arlene O.
AU - Gao, Jianjun
N1 - Publisher Copyright:
© 2016 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2016/5/25
Y1 - 2016/5/25
N2 - Immune checkpoint inhibitionwill be the first treatment breakthrough in recurrent andmetastatic urothelial carcinoma since the introduction of combination chemotherapy more than 30 years ago. Monoclonal antibodies that target cytotoxic T-lymphocyte antigen 4, programmed death receptor 1, and programmed death receptor ligand 1 are furthest along in clinical development. Specific antibodies targeting either programmed death receptor 1 or programmed death receptor ligand 1 have demonstrated significant single-agent activity with impressive safety and tolerability for heavily pretreated patients in early-phase clinical trials. In our review, we discuss the rationale for immunotherapy in urothelial cancer, completed and ongoing studies with immune checkpoint therapy, the development of molecular subtypes of urothelial carcinoma with the potential impact of immunotherapy in these new groupings, and future directions of exploration with these agents in both early-and late-stage disease.
AB - Immune checkpoint inhibitionwill be the first treatment breakthrough in recurrent andmetastatic urothelial carcinoma since the introduction of combination chemotherapy more than 30 years ago. Monoclonal antibodies that target cytotoxic T-lymphocyte antigen 4, programmed death receptor 1, and programmed death receptor ligand 1 are furthest along in clinical development. Specific antibodies targeting either programmed death receptor 1 or programmed death receptor ligand 1 have demonstrated significant single-agent activity with impressive safety and tolerability for heavily pretreated patients in early-phase clinical trials. In our review, we discuss the rationale for immunotherapy in urothelial cancer, completed and ongoing studies with immune checkpoint therapy, the development of molecular subtypes of urothelial carcinoma with the potential impact of immunotherapy in these new groupings, and future directions of exploration with these agents in both early-and late-stage disease.
KW - Bladder
KW - Immune checkpoint therapy
KW - Immunotherapy
KW - Urothelial carcinoma
UR - http://www.scopus.com/inward/record.url?scp=84969529179&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84969529179&partnerID=8YFLogxK
U2 - 10.1097/PPO.0000000000000175
DO - 10.1097/PPO.0000000000000175
M3 - Review article
C2 - 27111904
AN - SCOPUS:84969529179
SN - 1528-9117
VL - 22
SP - 96
EP - 100
JO - Cancer Journal (United States)
JF - Cancer Journal (United States)
IS - 2
ER -